Sign Out
Genotropin has given rise to the formation of antibodies to growth hormone and E. coli protein in a small number of patients.
The binding capacity of these antibodies has been low and without clinical significance. Investigation of eventful formation of antibodies should be performed if expected effect on the growth does not take place.
Leukemia has been reported in a small number of children who have been treated with growth hormone.
View ADR Monitoring Form
